Acerta Pharma B.V.

The sponsor demonstrates concentrated expertise in B-cell malignancies, with particular emphasis on chronic lymphocytic leukemia and mantle cell lymphoma. Research initiatives explore novel therapeutic approaches for patients with relapsed or refractory disease, including those who have experienced treatment failure with prior therapies. The investigational portfolio addresses both treatment-naïve populations and patients with progressive disease following Bruton's tyrosine kinase inhibitor therapy.

• Chronic Lymphocytic Leukemia Treatment Optimization
• Mantle Cell Lymphoma Therapeutic Strategies
• Relapsed and Refractory B-Cell Malignancies

Clinical programs evaluate combination regimens incorporating targeted kinase inhibitors with established immunotherapeutic agents, aiming to enhance treatment efficacy while managing safety profiles in diverse patient populations.